Acadia Pharmaceuticals vs Legend Biotech
Acadia Pharmaceuticals and Legend Biotech are similar in size: $1.07bn and $1.03bn of revenue in their latest fiscal years. Legend Biotech grew faster (64.0% against 11.9%). Acadia Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.5% against -28.8%. Acadia Pharmaceuticals carries less debt relative to equity (0.0% against 31.8%).
| Latest fiscal year | Acadia PharmaceuticalsACAD, 2025 | Legend BiotechLEGN, 2025 |
|---|---|---|
| Revenue | $1.07bn | $1.03bn |
| Revenue growth | 11.9% | 64.0% |
| Net income | $391m | −$297m |
| Operating margin | 9.8% | -13.3% |
| Net margin | 36.5% | -28.8% |
| Return on equity | 39.9% | -29.1% |
| Free cash flow | $105m | −$129m |
| Cash | $178m | $902m |
| Total debt | $0 | $319m |
| Debt to equity | 0.0% | 31.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 798 | — |
| Market value | $3.55bn | $3.97bn |
| Price vs our value range | — | — |
| Moat score | 44 (Weak) | — |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 5 sales |